18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation.

[1]  Quynh-Thu Le,et al.  Non-small cell lung cancer: Clinical practice guidelines in oncology , 2006 .

[2]  M. Bonnen,et al.  Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients. , 2001, International journal of radiation oncology, biology, physics.

[3]  Jeffrey D Bradley,et al.  Molecular (functional) imaging for radiotherapy applications: an RTOG symposium. , 2003, International journal of radiation oncology, biology, physics.

[4]  L. Ellis,et al.  Response to preoperative chemoradiation increases the use of sphincter‐preserving surgery in patients with locally advanced low rectal carcinoma , 2003, Cancer.

[5]  J. Batlle,et al.  Efficacy of Preoperative Radiation Therapy for Resectable Rectal Adenocarcinoma When Combined With Oral Tegafur-Uracil Modulated With Leucovorin: Results From a Phase II Study , 2002 .

[6]  P. Navarria,et al.  Combined treatment of non metastatic intracranial germinoma in childhood: impact of radiotherapy volume extent , 2002 .

[7]  K. Song,et al.  Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. , 2002, International journal of radiation oncology, biology, physics.

[8]  J. Batlle,et al.  Efficacy of Preoperative Radiation Therapy for Resectable Rectal Adenocarcinoma When Combined With Oral Tegafur-Uracil Modulated With Leucovorin , 2002, Diseases of the colon and rectum.

[9]  K. Ohtomo,et al.  FDG-PET after radiotherapy is a good prognostic indicator of rectal cancer , 2002, Annals of nuclear medicine.

[10]  V. Valentini,et al.  Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer? A long-term analysis of 165 patients. , 2002, International journal of radiation oncology, biology, physics.

[11]  C. Taylor,et al.  T-Level Downstaging and Complete Pathologic Response After Preoperative Chemoradiation for Advanced Rectal Cancer Result in Decreased Recurrence and Improved Disease-Free Survival , 2002, Diseases of the colon and rectum.

[12]  K. Mcmullen,et al.  Chemoradiation with novel agents for rectal cancer. , 2002, Clinical colorectal cancer.

[13]  F. C. Calvo Manuel,et al.  Ano-rectal sphincter preservation following preoperative chemoradiation in cT3–4Nx rectal cancer: influence of tumor distance and downstaging , 2002, Revista de Oncología.

[14]  M. Schwaiger,et al.  PET imaging with [11C]methyl-L-methionine for therapy monitoring in patients with rectal cancer , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[15]  Mohamed Allaoua,et al.  Standardized uptake value of 2-[(18)F] fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  F. Calvo,et al.  Pathologic downstaging of T3-4Nx rectal cancer after chemoradiation: 5-fluorouracil vs. Tegafur. , 2001, International journal of radiation oncology, biology, physics.

[17]  M. Flentje,et al.  Adjuvant radio-chemotherapy for rectal cancer stage UICC II and III: results of a German patterns-of-care study including 534 patients from 6 institutions , 2001 .

[18]  V. Valentini,et al.  Ten years of preoperative chemoradiation for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, and sphincter preservation in three consecutive studies. , 2001, International journal of radiation oncology, biology, physics.

[19]  T. Yeatman,et al.  Local Excision of T2 and T3 Rectal Cancers After Downstaging Chemoradiation , 2001, Annals of surgery.

[20]  J Aoki,et al.  FDG PET of primary benign and malignant bone tumors: standardized uptake value in 52 lesions. , 2001, Radiology.

[21]  L. Mortelmans,et al.  Clinical value of whole-body positron emission tomography in potentially curable colorectal liver metastases☆ , 2001 .

[22]  C. Rödel,et al.  Perioperative radiotherapy and concurrent radiochemotherapy in rectal cancer. , 2001, Seminars in surgical oncology.

[23]  L. Mortelmans,et al.  Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases. , 2001, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[24]  D. Hossfeld,et al.  Rectal Cancer: Integrating Oxaliplatin Into Chemoradiation Studies , 2000 .

[25]  W. Regine,et al.  Prognostic significance of postchemoradiation stage following preoperative chemotherapy and radiation for advanced/recurrent rectal cancers. , 2000, International journal of radiation oncology, biology, physics.

[26]  J. Schofield,et al.  The cost-effectiveness and cost-utility of high-dose palliative radiotherapy for advanced non-small-cell lung cancer. , 2000, International journal of radiation oncology, biology, physics.

[27]  Sung-Cheng Huang,et al.  Anatomy of SUV , 2000 .

[28]  M. Graham,et al.  Comparison of simplified quantitative analyses of FDG uptake. , 2000, Nuclear medicine and biology.

[29]  J. Fleshman,et al.  Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum , 2000, Diseases of the colon and rectum.

[30]  Larson,et al.  Whole-Body FDG-PET in Patients with Recurrent Colorectal Carcinoma. A Comparative Study with CT. , 2000, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[31]  C. Hoh,et al.  Positron emission tomography: an independent indicator of radiocurability in head and neck carcinomas. , 2000, American journal of clinical oncology.

[32]  J. Humm,et al.  Prospective assessment of primary rectal cancer response to preoperative radiation and chemotherapy using 18-fluorodeoxyglucose positron emission tomography , 2000, Diseases of the colon and rectum.

[33]  S C Huang,et al.  Anatomy of SUV. Standardized uptake value. , 2000, Nuclear medicine and biology.

[34]  D. Ryan.  Rectal cancer: integrating oxaliplatin into chemoradiation studies. , 2000, Oncology.

[35]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[36]  A. Brugarolas,et al.  [Value of Pet-18FDG in lung cancer]. , 1999, Medicina clinica.

[37]  P. Dupont,et al.  Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  J. Ajani,et al.  Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancer. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[39]  V. Valentini,et al.  The accuracy of transrectal ultrasound in predicting the pathological stage of low-lying rectal cancer after preoperative chemoradiation therapy. , 1999, International journal of radiation oncology, biology, physics.

[40]  P. Dupont,et al.  Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  Y. Koide,et al.  Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[42]  H. Abdel-Nabi,et al.  Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. , 1998, Radiology.

[43]  H. Minn,et al.  Prediction of survival with fluorine-18-fluoro-deoxyglucose and PET in head and neck cancer. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[44]  H. Biersack,et al.  Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice , 1997, Diseases of the colon and rectum.

[45]  G. V. von Schulthess,et al.  Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. , 1997, Radiology.

[46]  H. Rockette,et al.  A clinical trial to evaluate the worth of preoperative multimodality therapy in patients with operable carcinoma of the rectum , 1997, Diseases of the colon and rectum.

[47]  M. Fulham,et al.  The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver. , 1996, Archives of surgery.

[48]  J. Keyes.  SUV: standard uptake or silly useless value? , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[49]  B. Glimelius,et al.  Predicting malignancy grade with PET in non-Hodgkin's lymphoma. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[50]  L M Hamberg,et al.  The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[51]  T. Fukumura,et al.  Assessment of response to cancer therapy using fluorine-18-fluorodeoxyglucose and positron emission tomography. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.